2024年第33届亚太肝病研究学会（APASL）年会于2024年3月27-31日在日本顺利召开。作为亚太地区最具权威性的肝病领域学术盛会之一，APASL年会每年均汇聚了来自亚太及全球各地的顶尖专家、学者和研究人员，共同探讨肝病领域的最新进展。本次年会主题广泛，涵盖了病毒性肝炎、酒精性肝病（ALD）、非酒精性脂肪性肝病（NAFLD）、药性肝损伤（DILI）、自身免疫性和遗传性肝病等多个热门领域。与会者们纷纷分享亚洲地区在肝脏病学领域取得的卓越成就，深入探讨了当前面临的诸多挑战，并展望了未来肝病研究的发展方向。
值此契机，医脉通特别邀请来自日本东京大学Masao Omata教授，结合APASL年会内容就“亚太地区肝癌预防策略：挑战、机遇与未来展望”进行深入解读，以期为广大医生分享学术见解，助力提高临床一线人员在肝癌综合诊治及研究水平。
医脉通：基于目前相关的调查与研究数据，请您谈谈亚太地区肝癌发病率的整体趋势如何？影响亚太地区肝癌高发的主要危险因素是什么？
YMT：Based on current relevant survey and research data, could you discuss the overall trend of liver cancer incidence in the Asia-Pacific region? What are the main risk factors contributing to the high incidence of liver cancer in this region?
Masao Omata教授：
在过去的四十年里，中国和日本在肝癌高发的主要风险因素上差异显著。以日本为例，约有80%的肝癌病例源于丙型肝炎病毒（HCV）感染。而反观中国，大多数肝癌病例则归因于乙型肝炎病毒（HBV）的感染，这形成了明显的对比。这种差异不仅体现了两国在疾病流行病学上的特色，也促使我们通过理解彼此的特殊情况和差异来加强交流，分享研究成果。
Prof Masao Omata：
In the past 40 years,China and Japan have significantly differed in the main risk factors for high incidence of liver cancer. Taking Japan as an example, about 80% of liver cancer cases are attributed to hepatitis C virus (HCV) infection. In contrast, in China, the majority of liver cancer cases are due to hepatitis B virus (HBV) infection, marking a stark contrast. This difference not only hreflects the characteristics of the two countries in the epidemiology of disease， but also encourages us to enhance communication and share research results by understanding each other's specific situations and differences.
医脉通：您认为目前临床针对这些危险因素的管理现状如何？面临的主要挑战有哪些？
YMT:How do you perceive the current clinical management status of these risk factors? What are the main challenges faced?
Masao Omata教授：
自1989年发现丙型肝炎病毒以来，日本在2015年便启动了相应的治疗策略，时至今日，日本几乎可以治愈近99%的HCV携带者，这一治疗策略大幅降低了日本由HCV引发的肝病致死率。曾经HCV导致的病例占70%-80%，现在可能降至30%-40%，这一显著变化堪称日本医学界的重大成功。
相比之下，中国面临着更为严峻的HBV挑战。在中国，HBV携带者众多，医学专家持续探索如何更有效地抑制病毒复制，以期降低肝癌的发病率。考虑到病毒的特性以及肝癌对于中国民众的潜在危险，我认为，中国在这一领域任重而道远。
Prof Masao Omata：
Since the discovery of the hepatitis C virus in 1989, Japan has launched a corresponding treatment strategy in 2015.To date, Japan has been able to cure nearly 99% of HCV carriers，significantly reducing the liver disease mortality rate caused by HCV in Japan. Cases of liver disease attributed to HCV once accounted for 70%-80% but have now possibly decreased to 30%-40%，marking a major success in the Japanese medical community.
In contrast, China faces a more severe challenge with hepatitis B virus (HBV). In China, there are many HBV carriers, and medical experts continue to explorehow to more effectively suppress viral replication in hopes of reducing the incidence of liver cancer..Considering the characteristics of the virus and the potential danger of liver cancer to the Chinesepopulation.I believe China has a long and challenging road ahead in this field.
医脉通：对于这些肝癌预防工作面临的挑战，请您分享一下目前有哪些创新的方法或策略来进一步改进肝癌预防的管理现状？
YMT:Regarding the challenges faced in liver cancer prevention work, could you share any innovative methods or strategies to further improve the management status of liver cancer prevention?
Masao Omata教授：正是因此，我们才在2024年齐聚京都召开APASL 2024。在此，我有幸与多位致力于抑制和根除肝炎病毒的中国专家交流。在此次会议中，他们可能会展示相关研究数据。
明年，我们将计划在北京举办APASL 2025，预计这将是一场规模庞大而质量卓越的学术盛会。届时，会议将在魏来教授的主持下进行，我对这次会议抱有期待，不仅仅是参会人数，更多的是期待在HBV根除等关键研究领域取得的实质性进展。
Prof Masao Omata：
That's why we we are having gathering here in APASL Kyoto 2024 . Here, I have the honor to communicate with several Chinese colleagues who are committed to suppressing and eradicating the hepatitis virus. At this conference, they may show such a kind of data.
Next year, we plan to hold APASL 2025 in Beijing, which is expected to be a large-scale and high-quality academic event. At that time, the meeting will be held under the chairmanship of Dr. Willian. I am looking forward to this meeting, not only the number of participants, but also the substantial progress made in key research areas such as HBV eradication.
医脉通：您认为对于未来的肝癌预防工作，亚太地区存在哪些具体优势和挑战？您有哪些展望？
YMT:In your opinion, what specific advantages and challenges does the Asia-Pacific region hold for future liver cancer prevention work? What are your prospects?
Masao Omata教授：目前，我们对于亚太地区肝癌预防的了解的仅如冰山一角，而挑战并非仅限于其广阔的地域面积，更在于70%的肝病患者、肝癌患者和其他疾病的患者都集中在某些特定区域。正如我之前提到的，不同地肝癌的病因各不相同。正因如此，我们需要像APASL这样的交流合作平台。通过深入交流，或许能收集并带回许多有益的信息到各自的国家，以便为所有国家的患者提供更好的服务和治疗。这正是我所期待的。
Prof Masao Omata：
At present, our understanding of liver cancer prevention in the Asia-Pacific region is only the tip of an iceberg, and the challenge is not limited to its vast area, but also that 70% of patients with hepatera, liver cancer and other diseases are concentrated in certain regions. As I mentioned before, the causes of liver cancerr is also different. That's why we need an exchange and cooperation platform like APASL. Through in-depth communication, it may be possible to collect and bring a lot of useful information back to their respective countries in order to provide better services and treatment for patients in all countries. This is exactly what I expected.
Professor Masao Omata
Yamanashi Central and Kita Hospitals, University of Tokyo，Honorary Professor
Major：Internal medicine, Surgery, Gastroenterology,Hepatocellular carcinoma and Endocrinology.
Social service：Honorary President of APASL 2024 Kyoto
